ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,976.97
      -1.13%
      US Tech 100
      21,079.20
      -1.25%
      Dow Jones
      42,197.79
      -1.79%
      Brent Oil
      73.815
      0.00%
      Bitcoin
      105,049.48
      -1.03%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Inozyme Pharma Inc (INZY) Quote

      Inozyme Pharma Inc

      Inozyme Pharma Inc (INZY)

      NASDAQ
      3.99
      0.01
      (0.25%)
      Closed June 14 4:00PM
      15 min delayed - Upgrade to Realtime
      3.98
      -0.01
      (-0.25%)
      After Hours: 5:34PM
      15 min delayed - Upgrade to Realtime

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      3.98
      Bid
      3.98
      Ask
      3.99
      Volume
      432,700
      3.97 Day's Range 3.99
      0.721 52 Week Range 6.24
      Market Cap
      256.956M
      Previous Close
      3.98
      Open
      3.98
      Last Trade
      5
      @
      3.99
      Last Trade Time
      Financial Volume
      $ 1,723,289
      VWAP
      3.9826
      Average Volume (3m)
      2,209,005
      Shares Outstanding
      64,561,824
      Dividend Yield
      -
      PE Ratio
      -2.52
      Earnings Per Share (EPS)
      -1.58
      Revenue
      -
      Net Profit
      -102.02M

      About Inozyme Pharma Inc

      Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 ... Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.inozyme.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Inozyme Pharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker INZY. The last closing price for Inozyme Pharma was $3.98. Over the last year, Inozyme Pharma shares have traded in a share price range of $ 0.721 to $ 6.24.

      Inozyme Pharma currently has 64,561,824 shares outstanding. The market capitalization of Inozyme Pharma is $256.96 million. Inozyme Pharma has a price to earnings ratio (PE ratio) of -2.52.

      Ask ADVFN Intelligence (AI)

      INZY Latest News

      More News

      Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
      Edgar (US Regulatory)
      June 04 2025
      INZY (0.25%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      June 02 2025
      INZY (0.25%)

      Form SC 14D9 - Solicitation, recommendation statements
      Edgar (US Regulatory)
      June 02 2025
      INZY (0.25%)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      Edgar (US Regulatory)
      May 14 2025
      INZY (0.25%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      May 14 2025
      INZY (0.25%)

      Form ARS - Annual Report to Security Holders
      Edgar (US Regulatory)
      April 29 2025
      INZY (0.25%)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1003.983.993.976194583.98020065CS
      40.030.7594936708863.953.993.7747745763.95710101CS
      123.0408323.7649063030.93923.990.72122090053.17132563CS
      261.0937.71626297582.893.990.72114075672.78749231CS
      52-1.02-20.456.240.7218769573.0793151CS
      156-0.28-6.572769953054.267.7950.7216714893.75141202CS
      260-13.95-77.802565532617.9331.64990.7214457624.44706223CS

      INZY - Frequently Asked Questions (FAQ)

      What is the current Inozyme Pharma share price?
      The current share price of Inozyme Pharma is $ 3.98
      How many Inozyme Pharma shares are in issue?
      Inozyme Pharma has 64,561,824 shares in issue
      What is the market cap of Inozyme Pharma?
      The market capitalisation of Inozyme Pharma is USD 256.96M
      What is the 1 year trading range for Inozyme Pharma share price?
      Inozyme Pharma has traded in the range of $ 0.721 to $ 6.24 during the past year
      What is the PE ratio of Inozyme Pharma?
      The price to earnings ratio of Inozyme Pharma is -2.52
      What is the reporting currency for Inozyme Pharma?
      Inozyme Pharma reports financial results in USD
      What is the latest annual profit for Inozyme Pharma?
      The latest annual profit of Inozyme Pharma is USD -102.02M
      What is the registered address of Inozyme Pharma?
      The registered address for Inozyme Pharma is CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
      What is the Inozyme Pharma website address?
      The website address for Inozyme Pharma is www.inozyme.com
      Which industry sector does Inozyme Pharma operate in?
      Inozyme Pharma operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      RBNERobin Energy Ltd
      $ 13.85
      (313.43%)
      		101.81M
      OPOceanPal Inc
      $ 1.63
      (125.45%)
      		80.28M
      LGHLWLion Group Holding Ltd
      $ 0.0052
      (116.67%)
      		6.87M
      NEONNeonode Inc
      $ 16.83
      (68.47%)
      		4.78M
      ICONIcon Energy Corporation
      $ 2.90
      (62.01%)
      		59.04M
      SBETSharpLink Gaming Inc
      $ 9.2275
      (-71.63%)
      		41.92M
      AIHSSenmiao Technology Ltd
      $ 0.381
      (-63.01%)
      		16.8M
      CHSNChanson International Holding
      $ 0.22
      (-60.00%)
      		15.15M
      KWMK Wave Media Ltd
      $ 2.91
      (-50.43%)
      		2.59M
      JZXNJiuzi Holdings Inc
      $ 1.56
      (-46.39%)
      		2.24M
      HCTIHealthcare Triangle Inc
      $ 0.0201
      (-33.00%)
      		856.89M
      GNLNGreenlane Holdings Inc
      $ 0.0101
      (-34.42%)
      		792.34M
      CGBSCrown LNG Holdings Ltd
      $ 0.1104
      (31.43%)
      		788.42M
      TSLLDirexion Daily TSLA Bull 2X Trust ETF
      $ 12.655
      (3.81%)
      		246.13M
      NVDANVIDIA Corporation
      $ 141.97
      (-2.09%)
      		180.81M

      INZY Discussion

      View Posts
      georgie18 georgie18 4 weeks ago
      Nope…🥳
      👍️0
      fink fink 4 weeks ago
      You get any of this
      👍️0
      georgie18 georgie18 4 months ago
      INZY...$1.52...🥳... https://schrts.co/DXWCIncw ...Reversal setting up here on this Oversold Chart...

      Most Recent News...https://www.globenewswire.com/news-release/2025/01/10/3007647/0/en/Inozyme-Pharma-Announces-Positive-Interim-Data-for-INZ-701-in-Infants-and-Young-Children-with-ENPP1-Deficiency-and-Key-Program-Updates.html
      👍️0
      tj9938 tj9938 7 months ago
      Taking a beating this week. 
      👍️0
      Monksdream Monksdream 9 months ago
      INZY under $6
      👍️0
      AJ Freely AJ Freely 2 years ago
      $INZY - 👆Up 7% Pre-Market/ Current Price $5.12
      Pivotal bioVenture Partners Fund I, L.P purchases
      835k shares equal to $4m investment
      👍️0
      Monksdream Monksdream 2 years ago
      INZY new 52 week high
      👍️0
      INFINITI INFINITI 2 years ago
      Loading
      👍️0
      Jess070283 Jess070283 2 years ago
      Have a feeling this about to squeeze into a halt soon…..
      👍️0
      tj9938 tj9938 2 years ago
      Great week so far. Gotta keep it movin.
      👍️0
      tj9938 tj9938 2 years ago
      Quietest board out there
      👍️0
      ErnieBilco ErnieBilco 3 years ago
      Grabbed a starter here today
      👍️0
      crudeoil24 crudeoil24 3 years ago
      INZ-701 is currently in a Phase 1/2 clinical trial for ENPP1 Deficiency. Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. It is also focused on developing a therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-binding cassette sub-family C member 6 (ABCC6) deficiencies. The Company's lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Inozyme Pharma 13G Filing From Deep Track Capital Shows New 8.11% Stake

      (i) Deep Track Capital, LP

      (ii) Deep Track Biotechnology Master Fund, Ltd.

      (iii) David Kroin

      INZY
      👍️0
      tw0122 tw0122 3 years ago
      I like the BioXc chart looks better. Thanks for all the good insight.
      👍️0
      crudeoil24 crudeoil24 3 years ago
      The offering is expected to close on or about April 19, 2022
      👍️0
      tw0122 tw0122 3 years ago
      This analyst know about the offering?
      Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the pricing of an underwritten offering of 16,276,987 shares of its common stock at a price of $3.69 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 3,523,013 shares of common stock at a price of $3.6899 per pre-funded warrant, for aggregate gross proceeds of approximately $73 million, before deducting underwriting discounts and commissions and other offering expenses. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of such pre-funded warrant. All of the securities are being offered by Inozyme. The offering is expected to close on or about April 19, 2022, subject to customary closing conditions.
      👍️0
      crudeoil24 crudeoil24 3 years ago
      PT > 33.00
      👍️0
      crudeoil24 crudeoil24 3 years ago
      H.C. Wainwright analyst Edward White maintained a Buy rating on Inozyme Pharma (INZY – Research Report) yesterday and set a price target of $33.00. The company's shares closed last Tuesday at $3.89, close to its 52-week low of $3.54. According to TipRanks.com, White is ranked 0 out of 5 stars with an average return of -19.5% and a 25.5% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics. Inozyme Pharma has an analyst consensus of Strong Buy, with a price target consensus of $30.00, a 541.0% upside from current levels.
      👍️0

      Your Recent History

      NASDAQ
      INZY
      Inozyme Pharma
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads